Organovo Holdings, Inc. (LON:0R02)
London
· Delayed Price · Currency is GBP · Price in USD 0.362
-0.013 (-3.41%)
At close: Feb 21, 2025
Organovo Holdings Employees
As of March 31, 2024, Organovo Holdings had 20 total employees, including 12 full-time and 8 part-time employees. The number of employees decreased by 4 or -16.67% compared to the previous year.
Employees
20
Change (1Y)
-4
Growth (1Y)
-16.67%
Revenue / Employee
5.13K GBP
Profits / Employee
-520.67K GBP
Market Cap
4.49M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 89,900 |
| GSK plc | 70,212 |
| Haleon | 25,408 |
| Smith & Nephew | 18,452 |
| Hikma Pharmaceuticals | 9,100 |
| ConvaTec Group | 10,136 |
| HUTCHMED (China) | 1,988 |
| Genus | 3,500 |
Organovo Holdings News
- 6 weeks ago - Organovo appoints Norman Staskey as CFO - Seeking Alpha
- 6 weeks ago - Organovo Announces Appointment of Norman Staskey as Chief Financial Officer - GlobeNewsWire
- 3 months ago - Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting - GlobeNewsWire
- 3 months ago - Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases - GlobeNewsWire
- 7 months ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July - Benzinga
- 7 months ago - Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis - GlobeNewsWire
- 9 months ago - Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease - GlobeNewsWire
- 10 months ago - Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) - GlobeNewsWire